Autotaxin in Pathophysiology and Pulmonary Fibrosis

Autotaxin in Pathophysiology and Pulmonary Fibrosis

Lysophospholipid signaling is emerging as a druggable regulator of pathophysiological responses, and especially fibrosis, exemplified by the relative ongoing clinical trials in idiopathic pulmonary fibrosis (IPF) patients. In this review, we focus on ectonucleotide pyrophosphatase-phosphodiesterase...

Full description

Bibliographic Details
Main Authors:	Ioanna Ninou, Christiana Magkrioti, Vassilis Aidinis
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-06-01
Series:	Frontiers in Medicine
Subjects:	autotaxin (ATX) lysophosphatidic acid (LPA) lysophosphatidic acid receptor (LPAR) g-proteins pulmonary fibrosis
Online Access:	https://www.frontiersin.org/article/10.3389/fmed.2018.00180/full

Similar Items

The Expression Regulation and Biological Function of Autotaxin
by: Xiaotian Zhang, et al.
Published: (2021-04-01)

Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis
by: Souvik Banerjee, et al.
Published: (2022-08-01)

Deregulated Lysophosphatidic Acid Metabolism and Signaling in Liver Cancer
by: Eleanna Kaffe, et al.
Published: (2019-10-01)

Endothelial Specific Deletion of Autotaxin Improves Stroke Outcomes
by: Susmita Bhattarai, et al.
Published: (2023-02-01)

Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors
by: M.A. Deken, et al.
Published: (2023-06-01)

Autotaxin in Breast Cancer: Role, Epigenetic Regulation and Clinical Implications
by: Andrianna Drosouni, et al.
Published: (2022-11-01)

A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis
by: Richell Booijink, et al.
Published: (2022-09-01)

Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target
by: Konstantinos Ntatsoulis, et al.
Published: (2021-10-01)

Role of autotaxin in systemic lupus erythematosus
by: Yumi Tsuchida, et al.
Published: (2023-04-01)

Autotaxin Inhibition with IOA-289 Decreases Breast Tumor Growth in Mice Whereas Knockout of Autotaxin in Adipocytes Does Not
by: Xiaoyun Tang, et al.
Published: (2023-05-01)

Autotaxin Has a Negative Role in Systemic Inflammation
by: Ioanna Nikitopoulou, et al.
Published: (2022-07-01)

Synthesis, Characterization, and in vivo Evaluation of a Novel Potent Autotaxin-Inhibitor
by: Daniel Hunziker, et al.
Published: (2022-01-01)

Autotaxin-LPA-LPP3 Axis in Energy Metabolism and Metabolic Disease
by: Anu Jose, et al.
Published: (2021-09-01)

Autotaxin inhibitor IOA-289 reduces gastrointestinal cancer progression in preclinical models
by: Matteo Centonze, et al.
Published: (2023-08-01)

Regulation of Tumor Immunity by Lysophosphatidic Acid
by: Sue Chin Lee, et al.
Published: (2020-05-01)

Autotaxin signaling facilitates β cell dedifferentiation and dysfunction induced by Sirtuin 3 deficiency
by: Cao, Huanyi, et al.
Published: (2023)

Autotaxin Activity in Chronic Subdural Hematoma: A Prospective Clinical Study
by: Theodosis Kalamatianos, et al.
Published: (2022-08-01)

Linking the Autotaxin-LPA Axis to Medicinal Cannabis and the Endocannabinoid System
by: Mathias C. Eymery, et al.
Published: (2024-03-01)

Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer
by: Sha She, et al.
Published: (2022-06-01)

Design and Development of Autotaxin Inhibitors
by: Yi Jia, et al.
Published: (2021-11-01)

Expression of proteins related to autotaxin–lysophosphatidate signaling in thyroid tumors
by: Eunah Shin, et al.
Published: (2019-08-01)

Effects of autotaxin and lysophosphatidic acid deficiencies on depression-like behaviors in mice exposed to chronic unpredictable mild stress
by: Chao Wang, et al.
Published: (2024-05-01)

Decrease in serum levels of autotaxin in COVID-19 patients
by: Takuya Shimura, et al.
Published: (2022-12-01)

Autotaxin/Lysophosphatidic Acid Axis: From Bone Biology to Bone Disorders
by: Candide Alioli, et al.
Published: (2022-03-01)

LPA receptor signaling: pharmacology, physiology, and pathophysiology
by: Yun C. Yung, et al.
Published: (2014-07-01)

Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells
by: Elisa Matas-Rico, et al.
Published: (2021-11-01)

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
by: Zulfikar S, et al.
Published: (2020-07-01)

Benzoxaboroles—Novel Autotaxin Inhibitors
by: Kristina Kraljić, et al.
Published: (2019-09-01)

ATX-LPA-Dependent Nuclear Translocation of Endonuclease G in Respiratory Epithelial Cells: A New Mode Action for DNA Damage Induced by Crystalline Silica Particles
by: Huiyuan Zheng, et al.
Published: (2023-01-01)

Increased β‐endorphin and autotaxin in patients with prurigo
by: Takahiro Ishikawa, et al.
Published: (2019-08-01)

Plasma Concentrations of Lysophosphatidic Acid and Autotaxin in Abstinent Patients with Alcohol Use Disorder and Comorbid Liver Disease
by: María Flores-López, et al.
Published: (2021-09-01)

Dual Role of Lysophosphatidic Acid Receptor 2 (LPA2) in Amyotrophic Lateral Sclerosis
by: Maria Puigdomenech-Poch, et al.
Published: (2021-03-01)

Autotaxin Implication in Cancer Metastasis and Autoimunne Disorders: Functional Implication of Binding Autotaxin to the Cell Surface
by: Olivier Peyruchaud, et al.
Published: (2019-12-01)

The Autotaxin-LPA Axis Emerges as a Novel Regulator of Smooth Muscle Cell Phenotypic Modulation during Intimal Hyperplasia
by: Utsab Subedi, et al.
Published: (2023-02-01)

Lysophosphatidic Acid Induces Ligamentum Flavum Hypertrophy Through the LPAR1/Akt Pathway
by: Tangjun Zhou, et al.
Published: (2018-02-01)

The Structural Binding Mode of the Four Autotaxin Inhibitor Types that Differentially Affect Catalytic and Non-Catalytic Functions
by: Fernando Salgado-Polo, et al.
Published: (2019-10-01)

The LPA<sub>3</sub> Receptor: Regulation and Activation of Signaling Pathways
by: Karina Helivier Solís, et al.
Published: (2021-06-01)

The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer
by: Derek J. Erstad, et al.
Published: (2017-05-01)

Emerging Roles of Lysophosphatidic Acid in Macrophages and Inflammatory Diseases
by: Shufan Jiang, et al.
Published: (2023-08-01)

Lysophosphatidic Acid Inhibits Insulin Signaling in Primary Rat Hepatocytes via the LPA3 Receptor Subtype and is Increased in Obesity
by: Susann Fayyaz, et al.
Published: (2017-09-01)